# US 2025/0144236 A1 · Nitrogen-branched non-linear pegylated lipid and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144236 A1
- Document ID: US20250144236A1
- Status: Published application
- Kind: A1
- Application number: 18/838,083
- Filed: 2023-04-11
- Published: 2025-05-08
- Earliest claimed: 2022-04-12
- Assignees: Xiamen Sinopeg Biotech Co., Ltd.
- Applicants: Xiamen Sinopeg Biotech Co., Ltd.
- Inventors: Wengui WENG; Chao LIU; Ailan WANG; Dandan CHEN; Sheng LIN; Guohua WEI; Qi ZHU; Congming LIN
- Web page: https://patentgrep.com/patent/US20250144236A1

## CPC

- A61K 48/0041: {the non-active part being polymeric}
- C08G 65/3312: {acyclic}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- C07C 217/18: the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C 217/28: having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C 219/04: the carbon skeleton being acyclic and saturated
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C 233/04: with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C 233/46: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 235/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 235/10: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 235/12: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 235/74: of a saturated carbon skeleton
- C07C 271/18: to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D 255/02: not condensed with other rings
- C07D 475/04: with a nitrogen atom directly attached in position 2
- C07D 487/04: Ortho-condensed systems
- C07K 5/0815: {with the first amino acid being basic}
- C08G 65/2606: {containing hydroxyl groups}
- C08G 65/33324: {acyclic}
- C08G 65/48: Polymers modified by chemical after-treatment
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- C07C 2601/16: the ring being unsaturated
- C08G 2650/30: branched
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A nitrogen-branched non-linear PEGylated lipid of Formula (1), wherein, X is —CRa< or (Ra is H or a C1-12 alkyl group); B1 and B2 are linking bonds or C1-20 alkylene groups; L1 and L2 are linking bonds or divalent linking groups; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ld is a linking bond or a divalent linking group; Ncore is a multivalent group of valence y+1, and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ≥10; Lx is a linking bond or a divalent linking group; XPEG is a polyethylene glycol component. The non-linear PEGylated lipid herein can realize better surface modification of LNP. The lipid nanoparticle pharmaceutical composition and its formulation exhibit higher drug efficacy, especially for nucleic acid drugs.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A PEGylated lipid of the general formula (1):
wherein, X is —CRa< or
and Ra is H or a C1-12 alkyl group;
B1 and B2 are each independently a linking bond or a C1-20 alkylene group;
L1 and L2 are each independently a linking bond or a divalent linking group;
R1 and R2 are each independently a C1-50 aliphatic hydrocarbon group or a C1-50 residue of aliphatic hydrocarbon derivative, containing 0 to 10 heteroatoms; the heteroatom is B, O, N, Si, P or S;
Ld is a linking bond or a divalent linking group;
Ncore is a multivalent group having a valence of y+1, and contains a trivalent nitrogen-atom branching core connected to Ld;
y is 2,3,4,5, 6, 7, 8 or 9, or y>10;
y instances of Lx are each independently a linking bond or a divalent linking group;
XPEG is a polyethylene glycol component; each of y instances of XPEG independently contains one, two, three or four RPEG; RPEG is a single-chain polyethylene glycol component containing at least 4 EO units, and the EO unit is —CH2CH2O— or —OCH2CH2—; RPEG in the same XPEG have the same terminal group T; T is a hydrogen atom, an alkyl group or R01-L01-, wherein L01 is a linking bond or a divalent linking group, and R01 is a functional group that can interact with bio-related substances;
the alkyl group, alkylene group, aliphatic hydrocarbon group, and residue of aliphatic hydrocarbon derivative are each independently substituted or unsubstituted;
the PEGylated lipid is monodisperse or polydisperse;
or a salt, tautomer, stereoisomer or solvate thereof.

### Claim 34 (depends on 33)

The PEGylated lipid of claim 33, wherein L1 and L2 correspond to any of the following cases:
Case (1): one of L1 and L2 is a linking bond, and the other is a divalent linking group;
Case (2): both L1 and L2 are linking bonds;
Case (3): both L1 and L2 are divalent linking groups, and L1 and L2 have the same or different structures;
in any of Case (1), Case (2) and Case (3), the divalent linking group is selected from the group consisting of —CH2—, —O—, —S—, —C(═O)—, —NRc—, and combinations thereof; wherein, Re is, at each occurrence, independently a hydrogen atom or a C1-5 alkyl group;
specifically, L1 and L2 are each independently selected from the group consisting of a linking bond, —O—, —NHC(═O)—, —C(═O)NH—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —C(═O)—, —C(═O)O—(CH2)x—OC(═O)—, —C(═O)O—(CH2)x—C(═O)O—, —OC(═O)—(CH2)x—OC(═O)—, —OC(═O)—(CH2)x—C(═O)O—, —C(═O)NH—(CH2)x—C(═O)O—, —C(═O)NH—(CH2)x—OC(═O)—, —NHC(═O)—(CH2)x—C(═O)O—, —NHC(═O)—(CH2)x—OC(═O)—, —C(═O)NH—(CH2)x—C(═O)NH—, —C(═O)NH—(CH2)x—NHC(═O)—, —NHC(═O)—(CH2)x—C(═O)NH—, and —NHC(═O)—(CH2)x—NHC(═O)—;
wherein x is an integer in the range of 2 to 8.

### Claim 35 (depends on 33)

The PEGylated lipid of claim 33, wherein B1 and B2 correspond to any of the following cases:
Case (1): one of B1 and B2 is a linking bond, and the other is a C1-20 alkylene group;
Case (2): both B1 and B2 are linking bonds;
Case (3): both B1 and B2 are C1-20 alkylene groups, and B1 and B2 have the same or different structures;
the C1-20 alkylene group has 0 to 4 hydrogen atoms replaced by 0 to 4 Rq; Rq is, at each occurrence, independently selected from the group consisting of —(CH2)tqC[(CH2)tqH]3, —(CH2)tqO(CH2)tqH, —(CH2)tqS(CH2)tqH, and —(CH2)tqN[(CH2)tqH]2, wherein tq is, at each occurrence, independently an integer in the range of 0 to 4.

### Claim 36 (depends on 33)

The PEGylated lipid of claim 33, wherein R1 and R2 are each independently selected from the group consisting of RL, RB, and Rr; R1 and R2 each independently contains 0 to 10 Rm substituents; Rm is, at each occurrence, independently a linear, branched or ring-containing C1-8 hydrocarbon group;
R1 and R2 each independently contains 0 to 4 carbon-carbon double bonds and/or 0 to 4 carbon-carbon triple bonds;
RL is selected from the group consisting of the following structures and cis-/trans-isomers thereof:
wherein, the structure of RB is
wherein X is CH or N; the t of RB is an integer in the range of 0 to 5; Be and Bf are each independently a linking bond or a C1-10 alkylene group; Le and Lf are each independently a linking bond, —O—, —OC(═O)—, —C(═O)O—, —NHC(═O)—, or —C(═O)NH—; Re and Rf are each independently a C1-12 alkyl group;
wherein, Rr is a ring-containing C4-30 alkyl group or C4-30 heteroalkyl group.

### Claim 37 (depends on 33)

The PEGylated lipid of claim 33, wherein each of y instances of XPEG independently has a linear or non-linear structure; the linear structure contains one RPEG; the non-linear structure contains two, three, or four RPEG and also contains a trivalent, tetravalent or pentavalent branching core, wherein the branching core is selected from the group consisting of the following structures:
wherein the right end is connected to Lx.

### Claim 38 (depends on 33)

The PEGylated lipid of claim 33, wherein the structure of RPEG is
wherein, ni is the degree of polymerization of the polyethylene glycol chain, being an integer in the range of 4 to 250, wherein the polyethylene glycol chain is polydisperse or monodisperse; the i in ni is an integer selected from 1 to m, and m is equal to the total number of RPEG in the PEGylated lipid.

### Claim 39 (depends on 38)

The PEGylated lipid of claim 38, wherein the ni of quantity m are each independently an integer in the range of 4 to 100.

### Claim 40 (depends on 38)

The PEGylated lipid of claim 38, wherein the number average molecular weight of RPEG is selected from 0.5 kDa to 20 kDa.

### Claim 41 (depends on 33)

The PEGylated lipid of claim 33, the structure of which is represented by the general formula (2) or (3):
wherein, y is 2 or 3;
when y is 2, Ncore is selected from the group consisting of
when y is 3, Ncore is
wherein, u1, u2, u3, and u4 are each independently a linking bond connected to Ld or Lx, and any two of u1, u2, u3, and u4 are not simultaneously connected to the same Ld or Lx;
wherein, Q is an electron-changing group, the number of which is 0, 1 or greater than 1; when the number of Q is greater than 1, any two Q have the same or different structures;
wherein, T is a methyl group.

### Claim 42 (depends on 41)

The PEGylated lipid of claim 41, wherein T is R01-L01-; wherein, L01 is a linking bond, or selected from the group consisting of —CH2—, —O—, —S—, —C(═O)—, —NH—, and combinations thereof;
L01 is specifically selected from the group consisting of a linking bond, —(CH2)r—, —NH(CH2)t—, —NH(CH2)tC(═O)NH(CH2)t, —O(CH2)t—, —NH(CH2)tC(═O)O(CH2)t, —OC(═O)(CH2)r—, —OC(═O)O(CH2)t, —OC(═O)(CH2)tC(═O)—, and —(CH2)tC(═O)NH(CH2)t; the left end of L01 is connected to R01; the t of L01 is an integer in the range of 1 to 4.

### Claim 43 (depends on 42)

The PEGylated lipid of claim 42, wherein R01 is a reactive group selected from the group consisting of a hydroxyl group, a thiol group, an active ester group, an active carbonate group, a sulfonate group, an amino group, a maleimide group, a succinimide group, a carboxyl group, an acyl chloride group, an aldehyde group, an azido group, a cyano group, an alkenyl group, an alkynyl group, an epoxyalkyl group, a rhodamine group, a folate residue, a biotin residue, a monosaccharide group, and a polysaccharide group, or a modified form thereof; the modified form is selected from the group consisting of the precursors of reactive groups, the active forms to which reactive groups are precursors, the active forms in which reactive groups are substituted, and the inactive forms in which reactive groups are protected; wherein, the precursors of reactive groups refer to the structures which can be transformed into the reactive groups through at least one process among oxidation, reduction, hydration, dehydration, electronic rearrangement, structural rearrangement, salt complexation and decomplexation, ionization, protonation, and deprotonation;
R01 is specifically selected from the group consisting of the following structures:

### Claim 44 (depends on 41)

The PEGylated lipid of claim 41, wherein y instances of Lx are each independently selected from the group consisting of a linking bond, a hydrocarbylene group, a heteroatom-containing divalent linking group, and combinations thereof;
the heteroatom-containing divalent linking group is specifically —O—, —S—, —S—S—, —C(═O)—, —C(═O)O—, —OC(═O)—, —OC(═O)O—, —NH—, —C(═O)NH—, —NHC(═O)—, —OC(═O)NH—, or —NHC(═O)O—;
the hydrocarbylene group is specifically a C1-5 alkylene group;
specifically, each Lx is independently selected from the group consisting of —(CH2)2—, —C(═O)—, —CH2C(═O)—, —C(═O)CH2—, —C(═O)(CH2)2—, —CH2CH2C(═O)OCH2CH2—, —C(═O)NH—, —C(═O)NH(CH2)3—, and —C(═O)(CH2)2OC(═O)—, wherein the right end of Lx is connected to Ncore.

### Claim 45 (depends on 41)

The PEGylated lipid of claim 41, wherein Ld is selected from the group consisting of a linking bond, —CH2—, —(CH2)2—, —CH2C(═O)O—, —CH2C(═O)OCH2—, —(CH2)2C(═O)O—, —(CH2)2C(═O)OCH2—, —(CH2)3OC(═O)—, —CH2C(═O)NH—, —CH2C(═O)NHCH2—, —(CH2)2C(═O)NH—, —(CH2)2C(═O)NHCH2—, —(CH2)3NHC(═O)—, —CH2C(═O)NHCH2C(═O)OCH2—, and —(CH2)3O(CH2)3NHCH2—.

### Claim 46 (depends on 41)

The PEGylated lipid of claim 41, the structure of which is selected from the group consisting of the following structures:

### Claim 47 (depends on 33)

A lipid composition containing a PEGylated lipid of claim 33.

### Claim 48 (depends on 47)

The lipid composition of claim 47, which contains another one or more types of lipids selected from the group consisting of phospholipid, steroid lipid, and cationic lipid, corresponding to any of the following cases:
Case (1): the lipid composition also contains a phospholipid;
Case (2): the lipid composition also contains a steroid lipid;
Case (3): the lipid composition also contains a cationic lipid;
Case (4): the lipid composition also contains a phospholipid and a steroid lipid;
Case (5): the lipid composition also contains a phospholipid and a cationic lipid;
Case (6): the lipid composition also contains a steroid lipid and a cationic lipid;
Case (7): the lipid composition also contains a phospholipid, a steroid lipid, and a cationic lipid.

### Claim 49 (depends on 48)

The lipid composition of claim 48, wherein the phospholipid is selected from the group consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-diundecanoyl-sn-glycero-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine, 1-hexadecyl-sn-glycero-3-phosphocholine, 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt, dioleoylphosphatidylserine, dipalmitoylphosphatidylglycerol, palmitoyloleoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dimyristoylphosphoethanolamine, 1-stearoyl-2-oleoyl-phosphatidyethanolamine, 1-stearoyl-2-oleoyl-phosphatidylcholine, sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, and compositions thereof.

### Claim 50 (depends on 48)

The lipid composition of claim 48, wherein the steroid lipid is selected from the group consisting of cholesterol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol tomatidine, ursolic acid, α-tocopherol, and compositions thereof.

### Claim 51 (depends on 48)

The lipid composition of claim 48, wherein the cationic lipid is selected from the group consisting of N,N-dioleyl-N,N-dimethylammonium chloride, N,N-distearyl-N,N-dimethylammonium bromide, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride, N,N-dimethyl-2,3-dioleyloxy-1-(dimethylamino)propane, 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine, N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine, 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane, 1,2-dilinoleyloxy-N,N-dimethylaminopropane, 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane, heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate,
and compositions thereof.

### Claim 52 (depends on 48)

The lipid composition of claim 48, wherein,
the molar percentage of PEGylated lipid in total lipids is 0.5 to 5%;
the molar percentage of cationic lipid in total lipids is 30 to 65%;
the molar percentage of phospholipid in total lipids is 7.5 to 13%;
the molar percentage of steroid lipid in total lipids is 35 to 50%.

### Claim 53 (depends on 47)

A lipid pharmaceutical composition containing a lipid composition of claim 47 and a drug selected from the group consisting of nucleic acid drug, genetic vaccine, anti-neoplastic drug, small molecule drug, peptide drug, and protein drug.

### Claim 54 (depends on 53)

The lipid pharmaceutical composition of claim 53, wherein the drug is a nucleic acid drug selected from the group consisting of DNA, RNA, antisense nucleic acid, plasmid, interfering nucleic acid, aptamer, antagomir, and ribozyme, wherein the RNA is selected from the group consisting of mRNA, saRNA, circRNA, miRNA, and siRNA.

### Claim 55 (depends on 53)

The lipid pharmaceutical composition of claim 53, which is used as a medicine selected from the group consisting of drugs for treating cancer, anti-infective agents, antibiotic agents, antiviral agents, antifungal agents, and vaccines.

### Claim 56 (depends on 53)

The lipid pharmaceutical composition of claim 53, which is an LNP-pharmaceutical composition, an LPP-pharmaceutical composition, or a PNP-pharmaceutical composition.
